58
Participants
Start Date
August 31, 2022
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2022
Nirmatrelvir/Ritonavir
Patients in both groups were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature \>38.5 ℃. The study group was given Nirmatrelvir 300mg/Ritonavir 100mg orally, q12h, for 5 days, and the control group not given any antiviral drugs.
Xiangao Jiang, Wenzhou
Xiangao Jiang
OTHER